Cordant, Inc. Intellia Therapeutics, Inc. Transaction History
Cordant, Inc.
- $192 Billion
- Q1 2025
A detailed history of Cordant, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cordant, Inc. holds 116 shares of NTLA stock, worth $1,028. This represents 0.0% of its overall portfolio holdings.
Number of Shares
116Holding current value
$1,028% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
333Shares Held
94.9MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$111 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$90.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$85.1 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$46.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$33.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $674M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...